Trends in birth weight and gestational age for infants born to HIV-infected, antiretroviral treatment-naive women in Malawi
- PMID: 22327871
- PMCID: PMC3329585
- DOI: 10.1097/INF.0b013e31824d9bd9
Trends in birth weight and gestational age for infants born to HIV-infected, antiretroviral treatment-naive women in Malawi
Abstract
Background: We analyzed birth outcomes among infants of treatment-naive, HIV-infected women from a series of mother-to-child transmission of HIV studies in Blantyre, Malawi.
Methods: Data from 6 prospective studies at 1 research site were analyzed. Mean birth weight (BW) and gestational age (GA), and frequency of low birth weight (LBW; <2500 g) and preterm (PT) birth (GA < 37 weeks) were estimated. We assessed risk factors for LBW and PT birth using mixed-effects logistic regression. Adjusted odds ratios (AOR) and 95% confidence intervals from earlier studies (1989-1994) and later studies (2000-2007) are presented separately.
Results: The analysis included 8874 HIV-exposed infants. Mean BW and GA ranged from 2793 to 3079 g, and from 37.8 to 39.0 weeks. Greater maternal age was consistently (during both the early and late periods) associated with lower odds of LBW and PT birth; AOR (95% confidence intervals) for both outcomes in the early and late periods, respectively, were 0.98 (0.96-1.00) and 0.97 (0.95-0.99). Female infant gender was consistently associated with higher odds of PT birth during both periods and with higher odds of LBW during the later period. During the early period, higher maternal education was associated with lower odds of LBW (AOR 0.67 [0.48-0.95]) and PT birth (AOR 0.70 [0.51-0.95]), and later birth year was associated with lower odds of PT birth (AOR 0.35 [0.19-0.70]).
Conclusions: BW and GA remained stable within each time period. This analysis provides important baseline information for monitoring HIV treatment effects on birth outcomes. Modifiable factors affecting BW and GA should continue to be explored.
Conflict of interest statement
Figures

References
-
- UNAIDS. UNAIDS report on the global AIDS epidemic 2010. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2010.
-
- Zolfo M, De Weggheleire A, Schouten E, Lynen L. Time for “test and treat” in prevention of mother-to-child transmission programs in low- and middle-income countries. J Acquir Immune Defic Syndr. 2010;55(3):287–9. - PubMed
-
- Lorenzi P, Spicher VM, Laubereau B, Hirschel B, Kind C, Rudin C, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS. 1998;12(18):F241–7. - PubMed
-
- Cotter AM, Garcia AG, Duthely ML, Luke B, O’Sullivan MJ. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis. 2006;193(9):1195–201. - PubMed
-
- Schulte J, Dominguez K, Sukalac T, Bohannon B, Fowler MG. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: Pediatric Spectrum of HIV Disease, 1989-2004. Pediatrics. 2007;119(4):e900–6. - PubMed
Publication types
MeSH terms
Grants and funding
- #5R03TW01199/TW/FIC NIH HHS/United States
- N01 CP033005/CP/NCI NIH HHS/United States
- U01 AI048005/AI/NIAID NIH HHS/United States
- R21-AI-33874-01/AI/NIAID NIH HHS/United States
- R03 TW001199/TW/FIC NIH HHS/United States
- U50 PS022061/PS/NCHHSTP CDC HHS/United States
- U50-CC0222061/CC/CDC HHS/United States
- N01-AI-35173-117/AI/NIAID NIH HHS/United States
- 5-U50-PS022061-05/PS/NCHHSTP CDC HHS/United States
- R24 HD042854/HD/NICHD NIH HHS/United States
- P01 AI026499/AI/NIAID NIH HHS/United States
- P01-AI-26499/AI/NIAID NIH HHS/United States
- U01-AI-48005/AI/NIAID NIH HHS/United States
- N01-CP-33005/CP/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical